Evaxion Biotech A/S ADR (EVAX) Stock Price, Quote & News

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 31 31 97 53

Website: evaxion.ai

Address:

Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark

Manwiththeplan Feb. 3 at 9:16 PM

$EVAX i feel news is coming...

0 · Reply

uptrend2025 Feb. 3 at 7:20 PM

$EVAX Partnership News?

0 · Reply

Manwiththeplan Feb. 3 at 2:34 PM

$EVAX will explode hard when news of partnership comes. Only problem is that i expected this news in 2025.

0 · Reply

Manwiththeplan Jan. 30 at 8:12 PM

Bought $ALZN $CING $EVAX

0 · Reply

Manwiththeplan Jan. 29 at 6:13 PM

$EVAX buy low sell high. Nothing changed yet with this company. Still the same potential and pipeline

1 · Reply

baldaldo Jan. 29 at 3:52 PM

$EVAX How about a spike so we can get out?

1 · Reply

Manwiththeplan Jan. 28 at 9:28 PM

$EVAX -40% in 3 months. Wow. Love biitech.

0 · Reply

asbpame Jan. 28 at 8:50 PM

$EVAX i put this stock in intensive care area and ignore it next months but still

0 · Reply

asbpame Jan. 28 at 5:34 PM

$EVAX

1 · Reply

Olsen71 Jan. 28 at 5:16 AM

$EVAX Hmm If there's no good news soon, I'm afraid we'll soon be below course 2 again 🤔

0 · Reply

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Jan 7, 2026, 8:00 AM EST - 27 days ago

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Dec 19, 2025, 12:43 PM EST - 6 weeks ago

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Dec 19, 2025, 7:00 AM EST - 6 weeks ago

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Dec 6, 2025, 2:00 PM EST - 2 months ago

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Nov 12, 2025, 8:00 AM EST - 2 months ago

Evaxion announce 2026 financial calendar

Nov 7, 2025, 5:10 PM EST - 3 months ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 6, 2025, 7:56 PM EST - 3 months ago

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 3 months ago

Evaxion announces business update and third quarter 2025 financial results

Nov 3, 2025, 9:00 AM EST - 3 months ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Oct 31, 2025, 9:05 AM EDT - 3 months ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 3 months ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 27, 2025, 8:00 AM EDT - 3 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 22, 2025, 5:13 PM EDT - 3 months ago

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Oct 17, 2025, 8:15 AM EDT - 3 months ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 13, 2025, 8:00 AM EDT - 4 months ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 8, 2025, 8:12 AM EDT - 4 months ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 3, 2025, 9:00 AM EDT - 4 months ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Sep 25, 2025, 11:07 AM EDT - 4 months ago

Evaxion A/S - Special Call

Sep 25, 2025, 7:00 AM EDT - 4 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Aug 19, 2025, 3:29 PM EDT - 6 months ago

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 8:00 AM EDT - 6 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Jul 25, 2025, 9:00 AM EDT - 6 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 11, 2025, 8:00 AM EDT - 7 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 1, 2025, 8:30 AM EDT - 7 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jun 25, 2025, 8:00 AM EDT - 7 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 3, 2025, 9:15 AM EDT - 8 months ago

Evaxion receives grant funding to design new polio vaccine

May 27, 2025, 10:43 AM EDT - 9 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 7:30 AM EDT - 9 months ago

Evaxion announces business update and first quarter 2025 financial results

May 26, 2025, 8:47 AM EDT - 9 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 23, 2025, 8:00 AM EDT - 9 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 22, 2025, 8:00 AM EDT - 9 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Apr 28, 2025, 8:00 AM EDT - 10 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 10, 2025, 8:00 AM EDT - 10 months ago

Evaxion to present at World Vaccine Congress

Apr 1, 2025, 11:21 AM EDT - 11 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:00 AM EDT - 11 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Feb 25, 2025, 8:00 AM EST - 1 year ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Jan 31, 2025, 4:05 PM EST - 1 year ago

Evaxion announces closing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 1 year ago

Evaxion announces pricing of $10.8 million public offering

Jan 28, 2025, 8:15 AM EST - 1 year ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 14, 2025, 4:05 PM EST - 1 year ago

Evaxion announces completion of ADS ratio change

Jan 10, 2025, 8:00 AM EST - 1 year ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 1 year ago

Evaxion announces plan to implement ADS ratio change

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Manwiththeplan Feb. 3 at 9:16 PM

$EVAX i feel news is coming...

0 · Reply

uptrend2025 Feb. 3 at 7:20 PM

$EVAX Partnership News?

0 · Reply

Manwiththeplan Feb. 3 at 2:34 PM

$EVAX will explode hard when news of partnership comes. Only problem is that i expected this news in 2025.

0 · Reply

Manwiththeplan Jan. 30 at 8:12 PM

Bought $ALZN $CING $EVAX

0 · Reply

Manwiththeplan Jan. 29 at 6:13 PM

$EVAX buy low sell high. Nothing changed yet with this company. Still the same potential and pipeline

1 · Reply

baldaldo Jan. 29 at 3:52 PM

$EVAX How about a spike so we can get out?

1 · Reply

Manwiththeplan Jan. 28 at 9:28 PM

$EVAX -40% in 3 months. Wow. Love biitech.

0 · Reply

asbpame Jan. 28 at 8:50 PM

$EVAX i put this stock in intensive care area and ignore it next months but still

0 · Reply

asbpame Jan. 28 at 5:34 PM

$EVAX

1 · Reply

Olsen71 Jan. 28 at 5:16 AM

$EVAX Hmm If there's no good news soon, I'm afraid we'll soon be below course 2 again 🤔

0 · Reply

Manwiththeplan Jan. 26 at 6:00 PM

$EVAX well, share price doesnt seem to concern new CEO much but a market cap of 32 million is very low.

1 · Reply

Stock_Catcher Jan. 26 at 1:19 AM

Money Monday Watchlist Pt. 6 $ASTI $LAC $EVAX $ASPI $RCAT Let's Find a 1000% Runner

0 · Reply

Stock_Catcher Jan. 25 at 1:01 AM

Video out just now on the Bullish Thesis on $QCLS $GME $OPTT $SIDU $EVAX and more stocks that can gap up next week https://www.youtube.com/watch?v=RHB-7B6GKzc

0 · Reply

Manwiththeplan Jan. 23 at 5:43 PM

$EVAX not very nice. This was my ticket to early retirement.

2 · Reply

Manwiththeplan Jan. 21 at 6:00 PM

$EVAX price is getting even more tempting for a buy out. Market cap is very low for potential. I hope mansgement can get this up again

0 · Reply

mountaindog Jan. 16 at 7:03 PM

$EVAX evidently a hard working management, they have a holy grail on hand, big player behind, still manage to fall over a fucking coin

0 · Reply

Manwiththeplan Jan. 15 at 1:18 PM

$EVAX i am getting less enthousiastic. Low market cap and nice pipeline. but i am waiting now 2 years for a deal. I also dont like the lack of communication about why the former CEO had to go. And i dont like the track record of the new CEO. I dont know Adeptimmune that well, but the charts dont look good. These milestones dont say anything. ...

2 · Reply

prismmarketview Jan. 13 at 4:31 PM

Evaxion $EVAX Expands AI-Immunology™ Platform into Autoimmune Diseases, Outlines 2026 Milestones https://prismmarketview.com/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases-outlines-2026-milestones/

0 · Reply

Manwiththeplan Jan. 13 at 3:24 PM

$EVAX i really don t like this. Auto immuun disease will be much harder to work with. What to feed to the AI platform? Looks to me that they are not able to make the promising AI tools profitable and they are now trying this to attract investors. I am not hapy.

0 · Reply

Manwiththeplan Jan. 13 at 2:53 PM

$EVAX why announcing these milestones a week in front ?

1 · Reply

Lenni_D Jan. 13 at 1:14 PM

$EVAX https://evaxion.ai/investors/press-releases/?press_release_id=10866 Evaxion expands AI-Immunology™ platform into autoimmune diseases

1 · Reply

Manwiththeplan Jan. 12 at 7:48 PM

$EVAX lets see what tomorrow will bring

0 · Reply

Market Cap	2.30M
Revenue (ttm)	3.34M
Net Income (ttm)	-10.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-316.47%
Debt to Equity Ratio	-4.95

Volume	57,600
Avg Vol	68,002
Day's Range	N/A - N/A
Shares Out	1.40M
Stochastic %K	76%
Beta	-0.24
Analysts	Strong Sell
Price Target	$13.25